Recombinant Mouse CP2CN Protein
| 货号： | GXP50320 |
|---|---|
| Swiss Prot： | E9Q5K4 |
| 种属： | Mouse |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 26–494aa |
| 标签： | Customize |
| 纯度： | >90% |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
价格：¥2580
货期：3-4周/weeks
规格：
说明书：
产品详情
| 产品名称： | Recombinant Mouse CP2CN Protein |
|---|---|
| 别名： | Cyp2c23 Cyp2c44 |
| 货号： | GXP50320 |
| Swiss Prot： | E9Q5K4 |
| 种属： | Mouse |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 26–494aa |
| 标签： | Customize |
| 纯度： | >90% |
| 实际分子量： | Depends On Tags |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
| 无载体： | Yes |
| 无动物源： | Yes |
| 制剂： | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
| 描述： | A cytochrome P450 monooxygenase involved in polyunsaturated fatty acids (PUFAs) metabolism and signaling (PubMed:15084647). Catalyzes preferentially the epoxidation of double bonds of PUFAs (PubMed:15084647). Converts arachidonic acid (ARA, C20:4(n-6)) primarily to stereospecific products 8R,9S-epoxyeicosatrienoate (EET) and 11R,12S-EET (PubMed:15084647). Plays a major role in the formation of EETs and hydroxy-EETs (HEETs) in kidney. Via EETs may inhibit the epithelial sodium channels (ENaCs) in nephron segments, preventing excessive sodium absorption during high dietary salt intake (PubMed:24368771, PubMed:24966089). Participates in the formation of anti-inflammatory hydroxyepoxyeicosatrienoic acids (HEETs) by converting 20-hydroxyeicosatetraenoic acid (20-HETE) to 20,8,9-HEET, an activator of PPARA (By similarity). Metabolizes eicosapentaenoic acid (EPA, C20:5(n-3)) to epoxyeicosatetraenoic acid (EETeTr) regioisomers, 8,9-, 11,12-, 14,15-, and 17,18- EETeTr, preferentially producing 17R,18S enantiomer (By similarity). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:15084647). {ECO:0000250|UniProtKB:P24470, ECO:0000269|PubMed:15084647, ECO:0000269|PubMed:24368771, ECO:0000269|PubMed:24966089}. |
| 活性测试： | Not Test |
| 复溶： |
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. 收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。 |
| 储存： |
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. 未开盖的干粉蛋白在 -20°C至-80°C可保存12个月； 复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。 |
